Hydrix

Hydrix is attending the Hamlyn Symposium on Medical Robotics in London this week, joining leading researchers, clinicians, and innovators working at the forefront of robotic surgery and medical technology. Over the past 20 years, our team has contributed to the development of a wide range of regulated medical systems, including surgical robotics, advanced imaging platforms, vascular and endovascular technologies, MRI-compatible devices, haptic systems, and non-invasive therapeutic ultrasound solutions. If you're attending Hamlyn and would like to discuss your technology, development challenges, or commercialisation pathway, we'd be pleased to connect. #HSMR26 #Hydrix #MedicalRobotics #SurgicalRobotics #MedTech #MedicalDevices #Ultrasound #Innovation

Hydrix will be attending Eurosatory 2026 next week, joining defence organisations, technology developers and industry leaders from around the world. With growing demand for resilient sensing, autonomous systems, embedded electronics and mission-critical software, defence programs increasingly require the integration of advanced technologies into deployable operational capabilities. Recent Hydrix announcements, including the formation of Hydrix Defence and our work supporting advanced quantum navigation technologies, reflect the strategic focus we are bringing to this sector. Peter Riddell and Peter R. Lewis AM will be representing Hydrix in Paris, meeting with existing partners and exploring new opportunities across European and allied defence markets. We look forward to the conversations ahead. #Eurosatory2026 #DefenceTech #DefenceTechnology #MissionCriticalSystems #AdvancedEngineering

Hydrix has earned a well-deserved reputation as the partner MedTech startups turn to when getting to market is non-negotiable. We bring a proven, repeatable approach to complex, regulated devices across surgical, cardiovascular, wearables, neuromodulation and robotics, taking programs from concept to commercial reality. Most importantly, our model enables significant development cost advantages, without compromising quality or regulatory rigor. If you’re pitching at Radar Forum and thinking about what comes next, let’s talk. https://www.hydrix.com #MTIRadarForum #startups #innovation #medtech #HealthInnovation #MedtechInnovator #hydrix

If you’re developing or commercialising next-generation cardiac technology, the challenge isn’t the idea, it’s making it work reliably in the real world. Hydrix has spent 15+ years engineering complex cardiovascular systems, including mechanical circulatory support and advanced cardiac platforms, where performance, safety, and regulatory readiness are non-negotiable. We work with teams to turn ambitious concepts into clinically viable systems, from architecture through to verification and transfer to manufacture. At #ACC26, we’re meeting with organisations tackling the hardest problems in cardiac care. If that’s you, let’s talk.

Hydrix has been selected by SynCardia Systems, a wholly owned subsidiary of Picard Medical, Inc (NYSE: PME), to commence development collaboration on the Emperor, SynCardia’s next-generation fully implantable Total Artificial Heart (TAH). Hydrix will collaborate with SynCardia, which will draw on decades of real-world patient experience with artificial hearts, to tackle some of the most demanding challenges in cardiac care. As a fully implantable TAH, Emperor is intended to eliminate the use of an external driver, offering greater convenience and increased patient mobility. This is exactly the kind of challenge where Hydrix will build on more than 15 years supporting global artificial heart and related circulatory support device development. The Hydrix team is thrilled at the opportunity to apply deep, multi-discipline engineering capability to safety-critical cardiac technologies and to work closely with teams such as SynCardia operating at the frontier of highly regulated, life-saving medical technologies. Patrick N.J. Schnegelsberg, CEO of SynCardia Systems, said: “Hydrix’s expertise and demonstrated track record in advancing complex cardiovascular technologies will support our shared objective of developing solutions for patients with advanced heart failure.” The development collaboration reflects Picard Medical’s focus on partnering with world-class engineering organizations capable of supporting long-term, high-value development programs for mission-critical, life-sustaining technologies. 🔗 SynCardia announcement: https://lnkd.in/g6NFQVSM 🔗 Hydrix market release: https://lnkd.in/guqbBJ6C #MedTech #MedicalDevices #DigitalHealth #HealthcareInnovation #HealthTech #Cardiology #HeartFailure #ArtificialHeart #MechanicalCirculatorySupport #CardiacCare

For over 15 years, Hydrix has partnered with global pioneers to develop advanced cardiac innovations, from artificial hearts and VADs to cutting-edge catheter-based systems. Many of these technologies are now entering First-in-Human trials, paving the way for life-saving breakthroughs. Ready to take your cardiac innovation to First-in-Human trials? Connect with us today. https://www.hydrix.com #Hydrix #Cardiovascular #MCS #MedTech #ClassIII #VAD #ArtificialHeart #FirstInHuman #Innovation #MedicalDevices #DesignExcellence